ArticleScientific reports2025
Construction and evaluation of a prognostic model for breast cancer based on aging related genes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aging plays an important role in the development of breast cancer (BRCA); however, the specific underlying mechanism remains unclear. In this study, consensus clustering was initially used to classify BRCA subtypes. Thereafter, differentially expressed genes were identified within BRCA datasets and across subtypes, with overlapping genes being selected for further analysis. Cox regression analysis was used to identify key genes to construct a risk model for predicting prognosis. Furthermore, GSVA was used for pathway enrichment analysis, the infiltration levels of various immune cells were assessed, and the correlation between immune checkpoints and risk scores was analyzed. Finally, the expression levels of the key genes were validated through qRT-PCR. In addition, we also investigated the role of CXCL14 overexpression in the proliferation, invasion, and migration of MDA-MB-231 and MCF-7 cells. Human peripheral blood lymphocytes were co-cultured with MDA-MB-231 and MCF-7 cells at a cell density ratio of 2:1, and the proportion of live CD8+ T cells was measured by flow cytometry. Cox analysis revealed JCHAIN, KRT15, and CXCL14 as key prognosis-related genes; therefore, these genes were used to construct the risk model. In addition, age and stage were identified as independent prognostic factors. GSVA showed pathway enrichment in various risk groups, with the infiltration levels of 27 immune cell types being correlated with the risk score. The high-risk group exhibited downregulation of LAG3, CD274, CTLA4, and PDCD1. qRT-PCR validated the downregulation of JCHAIN and CXCL14 in a specific subgroup. CXCL14 overexpression significantly inhibited the proliferation, invasion, and migration capabilities of breast cancer cells. Furthermore, CXCL14 further suppressed tumor occurrence and development by activating CD8+ T cell-mediated immune mechanisms. In this study, the aging-related genes JCHAIN, KRT15, and CXCL14 were identified as key biomarkers for predicting the prognosis of BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.